Prothena Corp PLC PRTA

Morningstar Rating
$7.97 −0.19 (2.33%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PRTA is trading at a LOCK|%HRq! premium.
Price
$8.17
Fair Value
LOCK|!mrT@C
Uncertainty
LOCK|Wdj
1-Star Price
LOCK|.XdPW?Z
5-Star Price
LOCK|^K$Lb>!
Economic Moat
LOCK|rN
Capital Allocation
—

News

Trading Information

Previous Close Price
$8.16
Day Range
$7.88–8.20
52-Week Range
$7.81–11.69
Bid/Ask
$7.95 / $7.98
Shares Outstanding
51.35M
Market Cap
$407.20M
Volume/Avg
197,029 / 462,182

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
8.17
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
6.41%

Company Profile

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
67

Valuation

Metric
PRTA
Price/Earnings (Normalized)
—
Price/Book Value
1.56
Price/Sales
8.17
Price/Cash Flow
363.72
Price/Earnings
PRTA

Financial Strength

Metric
PRTA
Quick Ratio
23.73
Current Ratio
23.95
Interest Coverage
—
Quick Ratio
PRTA

Profitability

Metric
PRTA
Return on Assets (Normalized)
−0.93%
Return on Equity (Normalized)
−1.04%
Return on Invested Capital (Normalized)
−3.94%
Return on Assets
PRTA

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|W%B@$#LOCK|Dqw>z$137B
Regeneron Pharmaceuticals Inc
REGN
LOCK|@<!fF$LOCK|$@S?$99B
Moderna Inc
MRNA
LOCK|f$@@^V?LOCK|r@$90B
argenx SE ADR
ARGX
LOCK|?C^K$@nLOCK|#Y$61B
BeOne Medicines Ltd ADR
ONC
LOCK|x@G#H!LOCK|l%$48B
Royalty Pharma PLC Class A
RPRX
LOCK|d>MX?XR#LOCK|<!Fc$31B
Incyte Corp
INCY
LOCK|j>K>#?LOCK|?>x$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|fnxSkk^LOCK|rZ!n$22B
BioNTech SE ADR
BNTX
LOCK|?wnDc!LOCK|RS>$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|!S!n>HCLOCK|&C$16B

Sponsor Center